{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:50:57Z","timestamp":1788565857237,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","heartrhythmjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.hrthm.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T04:14:37Z","timestamp":1456373677000},"page":"1410-1417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation"],"prefix":"10.1016","volume":"13","author":[{"given":"Henry D.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Waks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Steinhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zimetbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2016.02.016_bib1","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Cardiovascular drugs: dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2016.02.016_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2016.02.016_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction","volume":"341","author":"Torp-Pedersen","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hrthm.2016.02.016_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(00)03402-4","article-title":"Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial","volume":"356","author":"Kober","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2016.02.016_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/chd.12129","article-title":"Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease","volume":"9","author":"Banchs","year":"2014","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.hrthm.2016.02.016_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-5273(96)02856-2","article-title":"Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery","volume":"58","author":"Frost","year":"1997","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0002-8703(99)70363-7","article-title":"Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"137","author":"Norgaard","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2016.02.016_bib8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study","volume":"102","author":"Singh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2016.02.016_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5603\/CJ.a2013.0089","article-title":"Atrial fibrillation practice patterns among cardiac electrophysiologists and cardiologists","volume":"21","author":"Teme","year":"2014","journal-title":"Cardiol J"},{"key":"10.1016\/j.hrthm.2016.02.016_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.amjcard.2013.04.014","article-title":"Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide","volume":"112","author":"Brumberg","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.amjcard.2013.10.031","article-title":"Usefulness of pharmacologic conversion of atrial fibrillation during dofetilide loading without the need for electrical cardioversion to predict durable response to therapy","volume":"113","author":"Malhotra","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10840-015-9974-7","article-title":"Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival","volume":"42","author":"Khurshid","year":"2015","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib13","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1161\/01.CIR.101.21.e200","article-title":"Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration","volume":"101","author":"Grines","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2016.02.016_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10840-008-9290-6","article-title":"Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter","volume":"23","author":"Banchs","year":"2008","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1074248407299272","article-title":"Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function","volume":"12","author":"Mykytsey","year":"2007","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2016.02.016_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.genm.2010.06.001","article-title":"Gender in atrial fibrillation: ten years later","volume":"7","author":"Michelena","year":"2010","journal-title":"Gend Med"},{"key":"10.1016\/j.hrthm.2016.02.016_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1540-8159.2007.00902.x","article-title":"Acute conversion of persistent atrial fibrillation during dofetilide initiation","volume":"30","author":"Cotiga","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib18","article-title":"ECG Interpretation Criteria Physician\u2019s Guide\u2014Full Format Statements","year":"2007","journal-title":"Bothell, WA: Cardiac Science Corp"},{"key":"10.1016\/j.hrthm.2016.02.016_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0038-1634799","article-title":"Methodology of ECG interpretation in the Glasgow program","volume":"29","author":"Macfarlane","year":"1990","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.hrthm.2016.02.016_bib20","unstructured":"Dofetilide prescribing information. Tikosyn Web site. \u3008http:\/\/www.tikosynrems.com\/\u3009. Accessed September 1, 2015."},{"key":"10.1016\/j.hrthm.2016.02.016_bib21","unstructured":"Tikosyn (dofetilide) [package insert]. New York, NY: Pfizer Laboratories; 1999."},{"key":"10.1016\/j.hrthm.2016.02.016_bib22","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1046\/j.1540-8167.2003.90402.x","article-title":"Clinical experience with dofetilide in the treatment of patients with atrial fibrillation","volume":"14","author":"Prystowsky","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00005344-199610000-00016","article-title":"Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs","volume":"28","author":"Chen","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1540-8167.1996.tb00594.x","article-title":"Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy","volume":"7","author":"Cha","year":"1996","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2016.02.016_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacc.2007.01.024","volume":"49","author":"Kligfield","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527116001879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527116001879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:59:29Z","timestamp":1567627169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527116001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1547527116001879"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2016.02.016","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Heart Rhythm Society. Published by Heart Rhythm Society All rights reserved.","name":"copyright","label":"Copyright"}]}}